The European Medicines Agency has decided that Ipsen’s Sohonos (palovarotene) should not be authorized for use in the EU, but it has recommended in favor of approval for Bristol Myers Squibb’s Sotyktu (deucravacitinib).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?